Jun 2026 (Q2 FY26) — Aug 13, 2026
Belite Bio Q2 FY26 — Tinlarebant NDA Accepted with Priority Review
Read the full callBelite Bio (BLTE) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
Belite Bio earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Guidance
What management said, and what became of it
2 of 4 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Pediatric investigational plan initiation (Tinlarebant) | Initiate study | Dec 2025 | So we are initiating a PIP study, a pediatric study in London, where we will investigate Tinlarebant in patients of BH3311 and this will be the basis to inform regulatory processes for patients that are younger than 12 years old. | Delayed |
| Cash runway | about 4 years | Sep 2024 | we are extremely well funded into the future with a cash runway to commercialize Tinlarebant following a potential regulatory approval and to continue to advance our pipelines. | On Track |
2 of BELITE BIO, INC's 14 targets were missed. See which ones, and which are quietly gone. The 2 above are the free sample; 12 more targets are in the full ledger.
Claimed
- FDA accepted New Drug Application (NDA) for Tinlarebant with Priority Review, establishing a PDUFA date of February 12, 2027.
- Cash, cash equivalents, and U.S. treasury bills totaled $780 million, providing a strong runway for commercialization and pipeline advancement.
- Phase III DRAGON study results showed Tinlarebant treated subjects decreased qAF values by approximately 2% at month 25, compared to a 20% increase in the placebo group.
Qualified
- GAAP net loss increased to $28.4 million in Q2 FY26 from $16.3 million in Q2 FY25.
- R&D expenses increased to $18.2 million in Q2 FY26 from $11 million in Q2 FY25, primarily due to a confidential royalty payment.
- SG&A expenses increased to $16.7 million in Q2 FY26 from $6.5 million in Q2 FY25, driven by team expansion and professional service fees.
Price
$152.62 −0.07% · −$0.1
Performance +92.6% 1Y
1Y: $79.26 on 14 Oct 2025 → $152.62. High $193.61 (4 Sept 2026), low $79.26 (14 Oct 2025).
- Previous close
- $152.72
- 52-week range
- $79.26 – $193.61
- One year
- +87.82%
Overview
- Symbol
- BLTE
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
2 of 4 judged targets kept · 10 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Pediatric investigational plan initiation (Tinlarebant) | Initiate study | Dec 2025 | So we are initiating a PIP study, a pediatric study in London, where we will investigate Tinlarebant in patients of BH3311 and this will be the basis to inform regulatory processes for patients that are younger than 12 years old. | Delayed |
| Cash runway | about 4 years | Sep 2024 | we are extremely well funded into the future with a cash runway to commercialize Tinlarebant following a potential regulatory approval and to continue to advance our pipelines. | On Track |
Claimed
- FDA accepted New Drug Application (NDA) for Tinlarebant with Priority Review, establishing a PDUFA date of February 12, 2027.
- Cash, cash equivalents, and U.S. treasury bills totaled $780 million, providing a strong runway for commercialization and pipeline advancement.
- Phase III DRAGON study results showed Tinlarebant treated subjects decreased qAF values by approximately 2% at month 25, compared to a 20% increase in the placebo group.
Qualified
- GAAP net loss increased to $28.4 million in Q2 FY26 from $16.3 million in Q2 FY25.
- R&D expenses increased to $18.2 million in Q2 FY26 from $11 million in Q2 FY25, primarily due to a confidential royalty payment.
- SG&A expenses increased to $16.7 million in Q2 FY26 from $6.5 million in Q2 FY25, driven by team expansion and professional service fees.
The full ledger
Open BELITE BIO, INC’s full ledger
A free account opens 5 company ledgers a month. All 14 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 20, 2026
Belite Bio Q1 FY26 — NDA Rolling Submission Initiated & Strong Cash Position
Read the full callDec 2025 (Q4 FY25) — Mar 2, 2026
Belite Bio Q4 FY25 — Positive Phase III Stargardt Results & NDA Prep
Read the full callEvery analysed call
Belite Bio earnings calls (BLTE)
Financials
What the filings say
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 |
| Reserves | -18 | -27 | -40 | -72 | -108 | -185 |
| Total liabilities | — | 2 | 3 | 4 | 6 | 10 |
| Fixed assets | — | 0 | 1 | 0 | 0 | 0 |
| Total assets | — | 18 | 44 | 95 | 152 | 781 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -4 | -7 | -11 | -30 | -29 | -37 |
| Cash from investing | -0 | -0 | -0 | -0 | -111 | -305 |
| Cash from financing | 28 | -1 | 37 | 76 | 84 | 663 |
| Net cash flow | 24 | -8 | 25 | 46 | -56 | 321 |
| Capital expenditure | — | -0 | -0 | -0 | -0 | -0 |
| Free cash flow | — | -8 | -12 | -30 | -29 | -37 |
Insider filings
177 filings between Apr 9, 2026 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$40.63M
175 sales by 5 insiders
93% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Lin Yu-Hsin | — | $20.82M | Sep 8, 2026 |
| Chuang Hao-Yuan | — | $14.00M | Sep 8, 2026 |
| Scholl Hendrik Peter | — | $2.94M | Oct 1, 2026 |
| MATA NATHAN L. | — | $2.67M | May 7, 2026 |
| Chen Wan-Shan | — | $198.5K | Apr 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 14 | $2.4K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 200 | $32.7K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 120 | $19.9K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 24 | $4.0K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 50 | $8.3K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 78 | $13.1K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 12 | $2.0K |
| Oct 1, 2026 | Scholl Hendrik Peter Chief Medical Officer | Sale 10b5-1 plan | 2 | $340 |
| Sep 8, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 8,752 | $1.73M |
| Sep 8, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 6,058 | $1.19M |
| Sep 8, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 2,700 | $534.8K |
| Sep 8, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 4,475 | $879.2K |
| Sep 8, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 4,605 | $908.2K |
| Sep 8, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 2,562 | $507.4K |
| Sep 8, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 6,090 | $1.19M |
| Sep 8, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 4,120 | $805.9K |
| Sep 8, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 2,400 | $466.4K |
| Sep 8, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 2,200 | $427.4K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 7,800 | $1.45M |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 2,587 | $468.9K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 6,200 | $1.16M |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 6,252 | $1.15M |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 4,593 | $851.3K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 2,000 | $365.0K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 1,633 | $294.2K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 3,413 | $622.9K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 3,045 | $573.3K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 8,955 | $1.70M |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 1,900 | $358.3K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 2,635 | $475.1K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 600 | $114.2K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 4,955 | $908.2K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 6,200 | $1.17M |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 11,080 | $2.12M |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 2,000 | $362.1K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 1,800 | $343.1K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 6,200 | $1.18M |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 8,111 | $1.57M |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 3,398 | $653.8K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 4,602 | $888.7K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 3,569 | $658.7K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 3,759 | $688.9K |
| Sep 4, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 4,209 | $810.4K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 3,872 | $717.4K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 3,900 | $729.9K |
| Sep 4, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 4,600 | $857.2K |
| Aug 12, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 223 | $40.3K |
| Aug 12, 2026 | Lin Yu-Hsin Chief Executive Officer | Sale 10b5-1 plan | 142 | $25.6K |
| Aug 12, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 223 | $40.3K |
| Aug 12, 2026 | Chuang Hao-Yuan Chief Financial Officer | Sale 10b5-1 plan | 144 | $25.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BELITE BIO, INC
Free account. Everything above stays public.
Write why you follow BELITE BIO, INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading